The role of secondary surgery in recurrent ovarian cancer

D. Lorusso, M. Mancini, R. Di Rocco, R. Fontanelli, F. Raspagliesi

Research output: Contribution to journalArticle

Abstract

Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30 and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.

Original languageEnglish
Article number613980
JournalInternational Journal of Surgical Oncology
Volume2012
DOIs
Publication statusPublished - 2012

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this